ARCT vs DMAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ARCT counters with relative strength in Valuation. Fundamentally, ARCT trades at 2.5x Forward P/E with -311.2% operating margin (+6.7% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ARCT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ARCT Revenue | DMAC Revenue | ARCT Op. Margin | DMAC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $20M | $0M | -138.5% | -1352.2% | ARCT |
| FY2019 | $20M | N/A | -122.7% | N/A | ARCT |
| FY2020 | $10M | N/A | -749.8% | N/A | ARCT |
| FY2021 | $10M | N/A | -1641.3% | N/A | ARCT |
| FY2022 | $210M | N/A | 5.9% | N/A | ARCT |
| FY2023 | $170M | N/A | -46.9% | N/A | ARCT |
| FY2024 | $150M | N/A | -62.8% | N/A | ARCT |
| FY2025 | $80M | N/A | -93.0% | N/A | ARCT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ARCT | DMAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $241.0M | $503.1M | Larger Scale | DMAC |
| Trailing P/E Ratio Valuation | 2.5x | N/M | Lower Multiple | ARCT |
| Forward P/E Ratio Valuation | 2.5x | N/M | Lower Multiple | ARCT |
| Revenue Growth (YoY) Growth | +6.7% | +0.0% | Higher Growth | ARCT |
| Operating Margin (TTM) Profitability | -311.2% | 0.0% | Higher Margin | DMAC |
| Net Profit Margin Profitability | -285.9% | 0.0% | Higher Margin | DMAC |
| Return on Equity (ROE) Capital Efficiency | -44.4% | -114.6% | Higher ROE | ARCT |
| 52-Week Range Position Momentum | 24% ($6โ$18) | 55% ($5โ$11) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 2.01ฮฒ ยท 127% Vol | 1.72ฮฒ ยท 97% Vol | Lower Realized Risk | DMAC |
| Unified Institutional Score Composite Signal | 57.7 / 100 (HOLD) | 46.3 / 100 (HOLD) | Higher Composite | ARCT |